
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
This AJMC® Clinical Brief focuses on managed care considerations for the treatment of spinal muscular atrophy.






